NCT05995041View on ClinicalTrials.gov

Universal CAR-T Cells Targeting AML

PHASE1RecruitingINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

October 31, 2023

Primary Completion Date

September 30, 2026

Study Completion Date

December 31, 2026

Conditions
Acute Myeloid Leukemia
Interventions
BIOLOGICAL

CLL-1, CD33, CD38 and/or CD123-specific universal CAR- T cells

Infusion of CLL-1, CD33, CD38 and/or CD123-specific universal CAR- T cells

Trial Locations (1)

518000

RECRUITING

Shenzhen Geno-Immune Medical Institute, Shenzhen

All Listed Sponsors
lead

Shenzhen Geno-Immune Medical Institute

OTHER